Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2026-01-06 Transaction in Own Shar…
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Ipsen – Half year statement – 2025 12 31
Transaction in Own Shares Classification · 1% confidence The document is a press release detailing the half-year status of a liquidity agreement between Ipsen and NATIXIS ODDO BHF. It provides specific data on share counts, cash balances, and trading volumes within the liquidity account. This type of disclosure regarding share buyback programs and liquidity management falls under the category of 'Transaction in Own Shares' (POS), as it reports on the company's activity in its own shares via a liquidity provider.
2026-01-06 English
Ipsen - Bilan semestriel - 31 12 2025
Transaction in Own Shares Classification · 1% confidence The document is a press release from Ipsen regarding the 'Bilan semestriel du contrat de liquidité' (semi-annual report of the liquidity contract). This document details the transactions and resources held in a liquidity account managed by a third party (NATIXIS ODDO BHF). In financial reporting, disclosures regarding share buybacks, liquidity contracts, and transactions in own shares are classified under 'Transaction in Own Shares' (POS).
2026-01-06 French
Ipsen élargit son portefeuille de produits en développement précoce avec un conjugué anticorps-médicament innovant développé par Simcere Zaiming
Regulatory Filings Classification · 1% confidence The document is a press release from Ipsen announcing a new exclusive licensing agreement with Simcere Zaiming for the development of a drug candidate (SIM0613). This type of announcement regarding strategic partnerships, licensing, and R&D pipeline expansion is classified as a regulatory filing or general corporate announcement. Since it does not fit into specific categories like M&A (which usually refers to corporate takeovers/mergers of entities) or specific financial reports, it falls under the RNS (Regulatory Filings) category as a general corporate announcement.
2025-12-22 French
Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate
Regulatory Filings Classification · 1% confidence The document is a press release announcing an exclusive licensing agreement between Ipsen and Simcere Zaiming for the development and commercialization of a new drug candidate (SIM0613). This type of corporate announcement regarding mergers, acquisitions, or licensing/partnership deals is classified as M&A Activity (TAR) within the provided schema.
2025-12-22 English
Ipsen fait le point sur l'essai de Phase II FALKON chez les patients atteints d’une maladie osseuse ultra-rare, la fibrodysplasie ossifiante progressive (FOP)
Regulatory Filings Classification · 1% confidence The document is a press release from Ipsen announcing the results of a Phase II clinical trial (FALKON) for the drug fidrisertib. It details that the trial did not meet its primary endpoint and will be closed. This type of announcement regarding clinical trial outcomes, research and development updates, and regulatory/scientific progress is classified as a Regulatory Filing (RNS) as it does not fit into specific categories like Earnings Release (which focuses on financial results) or Legal Proceedings.
2025-12-19 French
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)
Regulatory Filings Classification · 1% confidence The document is a press release from Ipsen announcing the results of a clinical trial (Phase II FALKON trial). It details the failure to meet primary endpoints and the subsequent closure of the study. This type of corporate announcement regarding clinical trial outcomes, which does not fit into specific financial reporting categories like 10-K or IR, is classified as a general regulatory filing or corporate announcement.
2025-12-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.